Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Naviscan

Request full access

High-resolution PET scanners for organ-specific molecular imaging

San Diego, United StatesFounded 1995Biotechnology

About Naviscan

Naviscan, now operating as CMR Naviscan after being acquired by Compañía Mexicana de Radiología (CMR) in 2013, specializes in organ-specific molecular imaging. The company was founded in 1995 and is headquartered in Carlsbad, California. It develops and manufactures high-resolution positron emission tomography (PET) scanners designed for imaging small body parts, with a primary application in breast cancer detection and management.

The company's flagship product is the PEM Flex® PET Scanner, which utilizes Positron Emission Mammography (PEM) technology to visualize breast tumors as small as a grain of rice (1.5-2.0 mm). This technology provides detailed 3D tomographic images that show both the location and metabolic phase of a lesion, a critical factor in determining malignancy and guiding treatment. The scanners are compact, mobile, and designed to be used as an adjunct to conventional imaging like mammography and ultrasound. Naviscan also developed the Stereo Navigator™, a PEM-guided biopsy system, which was the first of its kind to be cleared by the FDA. This allows for precise targeting of suspicious lesions identified with PEM, potentially reducing the number of unnecessary biopsies.

Naviscan's business model centers on the sale of these specialized medical imaging devices and related accessories to hospitals, breast clinics, and imaging centers. The technology serves radiologists, nuclear medicine physicians, surgeons, and oncologists. The company received crucial early-stage funding from the NCI SBIR program, which was instrumental in its research, development, and clinical trials leading to FDA clearance and commercialization in 2005. By 2013, the company had raised a total of $29.8M over 8 funding rounds from investors including QuestMark Partners and Sanderling Ventures before its acquisition by CMR. The acquisition by CMR and a subsequent acquisition of Gamma Medica allowed the company to expand its portfolio to include the LumaGEM Molecular Breast Imaging (MBI) system, further strengthening its offerings for breast cancer screening and diagnostics, particularly for women with dense breast tissue.

Source: Dealroom company data

Naviscan in the San Diego ecosystem

Live from Dealroom

The Naviscan office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Mayo Clinic
  • Sanderling Ventures

Series B and later2 investors entered at this stage

  • QuestMark Partners
  • Walker Ventures
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · San Diego HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Naviscan on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Naviscan on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.